Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Кардиоваскулярные риски у пациентов с псориазом (обзор литературы)

https://doi.org/10.33667/2078-5631-2021-34-12-17

Полный текст:

Аннотация

Статья носит обзорный характер и содержит актуальную информацию о коморбидной сердечно-сосудистой патологии при псориазе. Различные исследования показали, что псориаз связан с большей распространенностью факторов риска развития ССЗ, включая артериальную гипертензию, сахарный диабет, дислипидемию, ожирение и метаболический синдром. Обсуждаются связь между степенью тяжести псориаза и риском развития сердечно-сосудистых заболеваний, а также прогностические риски с показателями смертности. Предложенные общие патогенетические механизмы включают генетические факторы, воспалительные пути, секрецию адипокинов, инсулинорезистентность, состав и функцию липопротеинов, ангиогенез, оксидативный стресс и гиперкоагуляцию.

Об авторах

А. А. Хотко
ГБУЗ «Клинический кожно-венерологический диспансер» Минздрава Краснодарского края
Россия

Хотко Алкес Асланчериевич, к. м. н., доцент, зам. гл. врача

Краснодар



Н. С. Руднева
ФГБОУ ВО «Тульский государственный университет»
Россия

Руднева Наталья Сергеевна, к. м. н., гл. внештатный специалист – дерматовенеролог-косметолог Минздрава Тульской области, гл. врач

Тула



Список литературы

1. Augustin M., Radtke M. A. Quality of life in psoriasis patients. Expert Rev. Pharmacoecon. Outcomes Res. 2014; 14: 559–568.

2. Quintard B., Constant A., Bouyssou-Gauthier M.L., Paul C., Truchetet F., Thomas P., Guiguen Y., Taieb A. Validation of a specific health-related quality of life instrument in a large cohort of patients with psoriasis: The QualiPso Questionnaire. Acta Derm. Venereol. 2011; 91: 660–665.

3. Gelfand J. M., Neimann A. L., Shin D. B., Wang X., Margolis D. J., Troxel A. B. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296: 1735–1741.

4. Shahwan K. T., Kimball A. B. Psoriasis and cardiovascular disease. Med. Clin. N. Am. 2015; 99: 1227–1242.

5. Furue M., Tsuji G., Chiba T., Kadono T. Cardiovascular and Metabolic diseases comorbid with psoriasis: Beyond the skin. Intern. Med. 2017; 56: 1613–1619.

6. Mallbris L., Akre O., Granath F., Yin L., Lindelof B., Ekbom A., Stahle-Backdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur. J. Epidemiol. 2004; 19: 225–230.

7. Kaye J. A., Li L., Jick S. S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br. J. Dermatol. 2008; 159: 895–902.

8. Chiang C. H., Huang C. C., Chan W. L., Huang P. H., Chen Y. C., Chen T. J., Chung C. M., Lin S. J., Chen J. W., Leu H. B. Psoriasis and increased risk of ischemic stroke in Taiwan: A nationwide study. J. Dermatol. 2012; 39: 279–281.

9. Gelfand J. M., Dommasch E. D., Shin D. B., Azfar R. S., Kurd S. K., Wang X., Troxel A. B. The risk of stroke in patients with psoriasis. J. Investig. Dermatol. 2009; 129: 2411–2418.

10. Egeberg A., Thyssen J. P., Jensen P., Gislason G. H., Skov L. Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: A nationwide cohort study. Acta Derm. Venereol. 2017; 97: 819–824.

11. Heredi E., Vegh J., Pogacsas L., Gaspar K., Varga J., Kincse G., Zeher M., Szegedi A., Gaal J. Subclinical cardiovascular disease and it’s improvement after long-term TNF-alpha inhibitor therapy in severe psoriatic patients. J. Eur. Acad. Dermatol. Venereol. JEADV. 2016; 30: 1531–1536.

12. Langan S. M., Seminara N. M., Shin D. B., Troxel A. B., Kimmel S. E., Mehta N. N., Margolis D. J., Gelfand J. M. Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom. J. Investig. Dermatol. 2012; 132: 556–562.

13. Takeshita J., Wang S., Shin D. B., Mehta N. N., Kimmel S. E., Margolis D. J., Troxel A. B., Gelfand J. M. Effect of psoriasis severity on hypertension control: A population-based study in the United Kingdom. JAMA Dermatol. 2015; 151: 161–169.

14. Masson W., Rossi E., Galimberti M. L., Krauss J., Navarro Estrada J., Galimberti R., Cagide A. Mortality in patients with psoriasis. A retrospective cohort study. Med. Clin. 2017; 148: 483–488.

15. Lin H. W., Wang K. H., Lin H. C., Lin H. C. Increased risk of acute myocardial infarction in patients with psoriasis: A 5-year population-based study in Taiwan. J. Am. Acad. Dermatol. 2011; 64: 495–501.

16. Stern R. S., Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J. Investig. Dermatol. 2011; 131: 1159–1166.

17. Dregan A., Charlton J., Chowienczyk P., Gulliford M. C. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: A population-based cohort study. Circulation. 2014; 130: 837–844.

18. Shiba M., Kato T., Funasako M., Nakane E., Miyamoto S., Izumi T., Haruna T., Inoko M. Association between psoriasis vulgaris and coronary heart disease in a hospital-based population in Japan. PLoS ONE. 2016; 11: e0149316.

19. Benson M. M., Frishman W. H. The heartbreak of psoriasis: A review of cardiovascular risk in patients with psoriasis. Cardiol. Rev. 2015; 23: 312–316.

20. Abuabara K., Azfar R. S., Shin D. B., Neimann A. L., Troxel A. B., Gelfand J. M. Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U. K. Br. J. Dermatol. 2010; 163: 586–592.

21. Ogdie A., Yu Y., Haynes K., Love T. J., Maliha S., Jiang Y., Troxel A. B., Hennessy S., Kimmel S. E., Margolis D. J., et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Ann. Rheum. Dis. 2015; 74: 326–332.

22. Ahlehoff O., Gislason G., Lamberts M., Folke F., Lindhardsen J., Larsen C. T., Torp-Pedersen C., Hansen P. R. Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: A Danish nationwide cohort study. J. Intern. Med. 2015; 277: 447–455.

23. Samarasekera E. J., Neilson J. M., Warren R. B., Parnham J., Smith C. H. Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis. J. Investig. Dermatol. 2013; 133: 2340–2346.

24. Levesque A., Lachaine J., Bissonnette R. Risk of myocardial infarction in canadian patients with psoriasis: A retrospective cohort study. J. Cutan. Med. Surg. 2013; 17: 398–403.

25. Ahlehoff O., Gislason G. H., Charlot M., Jorgensen C. H., Lindhardsen J., Olesen J. B., Abildstrom S. Z., Skov L., Torp-Pedersen C., Hansen P. R. Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study. J. Intern. Med. 2011; 270: 147–157.

26. Miller I. M., Ellervik C., Yazdanyar S., Jemec G. B. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J. Am. Acad. Dermatol. 2013; 69: 1014–1024.

27. Chiu H. Y., Hsieh C. F., Chiang Y. T., Tsai Y. W., Huang W. F., Li C. Y., Wang T. S., Tsai T. F. Concomitant sleep disorders significantly increase the risk of cardiovascular disease in patients with psoriasis. PLoS ONE. 2016; 11: e0146462.

28. Dowlatshahi E. A., Wakkee M., Arends L. R., Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis. J. Investig. Dermatol. 2014; 134: 1542–1551.

29. Prodanovich S., Kirsner R. S., Kravetz J. D., Ma F., Martinez L., Federman D. G. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch. Dermatol. 2009; 145: 700–703.

30. Egeberg A., Khalid U., Gislason G. H., Mallbris L., Skov L., Hansen P. R. Impact of depression on risk of myocardial infarction, stroke and cardiovascular death in patients with psoriasis: A danish nationwide study. Acta Derm. Venereol. 2016; 96: 218–221.

31. Lu Y., Chen H., Nikamo P., Qi Low H., Helms C., Seielstad M., Liu J., Bowcock A. M., Stahle M., Liao W. Association of cardiovascular and metabolic disease genes with psoriasis. J. Investig. Dermatol. 2013; 133: 836–839.

32. Wolf N., Quaranta M., Prescott N. J., Allen M., Smith R., Burden A. D., Worthington J., Griffiths C. E., Mathew C. G., Barker J. N., et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J. Med. Genet. 2008; 45: 114–116.

33. Campalani E., Allen M. H., Fairhurst D., Young H. S., Mendonca C. O., Burden A. D., Griffiths C. E., Crook M. A., Barker J. N., Smith C. H. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br. J. Dermatol. 2006; 154: 345–352.

34. Koch M., Baurecht H., Ried J. S., Rodriguez E., Schlesinger S., Volks N., Gieger C., Ruckert I. M., Heinrich L., Willenborg C., et al. Psoriasis and cardiometabolic traits: Modest association but distinct genetic architectures. J. Investig. Dermatol. 2015; 135: 1283–1293.

35. Gupta Y., Moller S., Zillikens D., Boehncke W. H., Ibrahim S. M., Ludwig R. J. Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease. Exp. Dermatol. 2013; 22: 552–553.

36. Davidovici B. B., Sattar N., Prinz J., Puig L., Emery P., Barker J. N., van de Kerkhof P., Stahle M., Nestle F. O., Girolomoni G., et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J. Investig. Dermatol. 2010; 130: 1785–1796.

37. Youn S. W., Kang S. Y., Kim S. A., Park G. Y., Lee W. W. Subclinical systemic and vascular inflammation detected by (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with mild psoriasis. J. Dermatol. 2015; 42: 559–566.

38. Mehta N. N., Yu Y., Saboury B., Foroughi N., Krishnamoorthy P., Raper A., Baer A., Antigua J., Van Voorhees A. S., Torigian D. A., et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): A pilot study. Arch. Dermatol. 2011; 147: 1031–1039.

39. Wang Y., Gao H., Loyd C. M., Fu W., Diaconu D., Liu S., Cooper K. D., McCormick T.S., Simon D. I., Ward N. L. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J. Investig. Dermatol. 2012; 132: 2067–2075. DOI: 10.1038/jid.2012.112.

40. Boehncke W. H., Boehncke S., Tobin A. M., Kirby B. The ‘psoriatic march’: A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp. Dermatol. 2011; 20: 303–307.

41. Armstrong A. W., Voyles S. V., Armstrong E. J., Fuller E. N., Rutledge J. C. A tale of two plaques: Convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp. Dermatol. 2011; 20: 544–549.

42. Hashmi S., Zeng Q. T. Role of interleukin‑17 and interleukin‑17-induced cytokines interleukin‑6 and interleukin‑8 in unstable coronary artery disease. Coron. Artery Dis. 2006; 17: 699–706.

43. Owczarczyk-Saczonek A., Placek W. Interleukin‑17 as a factor linking the pathogenesis of psoriasis with metabolic disorders. Int. J. Dermatol. 2017; 56: 260–268.

44. Deng Y., Scherer P. E. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann. N. Y. Acad. Sci. 2010; 1212: e1–e19.

45. Cerman A. A., Bozkurt S., Sav A., Tulunay A., Elbasi M. O., Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br. J. Dermatol. 2008; 159: 820–826.

46. Stjernholm T., Ommen P., Langkilde A., Johansen C., Iversen L., Rosada C., Stenderup K. Leptin deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. Exp. Dermatol. 2017; 26: 338–345.

47. Oh Y. J., Lim H. K., Choi J. H., Lee J. W., Kim N. I. Serum leptin and adiponectin levels in Korean patients with psoriasis. J. Korean Med. Sci. 2014; 29: 729–734.

48. Li R. C., Krishnamoorthy P., DerOhannessian S., Doveikis J., Wilcox M., Thomas P., Rader D. J., Reilly M. P., Van Voorhees A., Gelfand J. M., et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin. Exp. Dermatol. 2014; 39: 19–24.

49. Robati R. M., Partovi-Kia M., Haghighatkhah H. R., Younespour S., Abdollahimajd F. Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: Is psoriasis associated with atherosclerosis? J. Am. Acad. Dermatol. 2014; 71: 642–648.

50. Li R. C., Krishnamoorthy P., DerOhannessian S., Doveikis J., Wilcox M., Thomas P., Rader D. J., Reilly M. P., Van Voorhees A., Gelfand J. M., et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin. Exp. Dermatol. 2014; 39: 19–24.

51. Holzer M., Wolf P., Inzinger M., Trieb M., Curcic S., Pasterk L., Weger W., Heinemann A., Marsche G. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J. Investig. Dermatol. 2014; 134: 635–642.

52. Chua R. A., Arbiser J. L. The role of angiogenesis in the pathogenesis of psoriasis. Autoimmunity. 2009; 42: 574–579.

53. Xu J., Lu X., Shi G. P. Vasa vasorum in atherosclerosis and clinical significance. Int. J. Mol. Sci. 2015; 16: 11574–11608.

54. Armstrong A. W., Voyles S. V., Armstrong E. J., Fuller E. N., Rutledge J. C. Angiogenesis and oxidative stress: Common mechanisms linking psoriasis with atherosclerosis. J. Dermatol. Sci. 2011; 63: 1–9.

55. Nielsen H. J., Christensen I. J., Svendsen M. N., Hansen U., Werther K., Brunner N., Petersen L. J., Kristensen J. K. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm. Res. 2002; 51: 563–567.

56. Brauchli Y. B., Jick S. S., Miret M., Meier C. R. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: An inception cohort study with a nested case-control analysis. Br. J. Dermatol. 2009; 160: 1048–1056.

57. Armstrong A. W., Harskamp C. T., Armstrong E. J. The association between psoriasis and hypertension: A systematic review and meta-analysis of observational studies. J. Hypertens. 2013; 31: 433–442, discussion 442–433.

58. Armstrong A. W., Harskamp C. T., Armstrong E. J. Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis. JAMA Dermatol. 2013; 149: 84–91.

59. Ma C., Harskamp C. T., Armstrong E. J., Armstrong A. W. The association between psoriasis and dyslipidaemia: A systematic review. Br. J. Dermatol. 2013; 168: 486–495.

60. Miller I. M., Skaaby T., Ellervik C., Jemec G. B. Quantifying cardiovascular disease risk factors in patients with psoriasis: A meta-analysis. Br. J. Dermatol. 2013; 169: 1180–1187.

61. Mysliwiec H., Baran A., Harasim-Symbor E., Mysliwiec P., Milewska A. J., Chabowski A., Flisiak I. Serum fatty acid profile in psoriasis and its comorbidity. Arch. Dermatol. Res. 2017; 309: 371–380.

62. Wu S., Li W. Q., Han J., Sun Q., Qureshi A. A. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheumatol. 2014; 66: 304–310.

63. Duarte G. V., Silva L. P. Correlation between psoriasis’ severity and waist-to-height ratio. Anais Brasileiros de Dermatologia. 2014; 89: 846–847.

64. Jacobi A., Langenbruch A., Purwins S., Augustin M., Radtke M. A. Prevalence of obesity in patients with psoriasis: Results of the national study PsoHealth3. Dermatology. 2015; 231: 231–238.

65. Herron M. D., Hinckley M., Hoffman M. S., Papenfuss J., Hansen C. B., Callis K. P., Krueger G. G. Impact of obesity and smoking on psoriasis presentation and management. Arch. Dermatol. 2005; 141: 1527–1534.

66. Wakkee M., Herings R. M., Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: Results of a large population- based Dutch cohort. J. Investig. Dermatol. 2010; 130: 962–967.

67. Jensen P., Christensen R., Zachariae C., Geiker N. R., Schaadt B. K., Stender S., Hansen P. R., Astrup A., Skov L. Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: A prospective observational follow-up study. Am. J. Clin. Nutr. 2016; 104: 259–265.

68. Naldi L., Peli L., Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: Evidence from an Italian case-control study. Arch. Dermatol. 1999; 135: 1479–1484.

69. Fortes C., Mastroeni S., Leffondre K., Sampogna F., Melchi F., Mazzotti E., Pasquini P., Abeni D. Relationship between smoking and the clinical severity of psoriasis. Arch. Dermatol. 2005; 141: 1580–1584.


Рецензия

Для цитирования:


Хотко А.А., Руднева Н.С. Кардиоваскулярные риски у пациентов с псориазом (обзор литературы). Медицинский алфавит. 2021;(34):12-17. https://doi.org/10.33667/2078-5631-2021-34-12-17

For citation:


Hotko A.A., Rudneva N.S. Cardiovascular risks in patients with psoriasis (literature review). Medical alphabet. 2021;(34):12-17. (In Russ.) https://doi.org/10.33667/2078-5631-2021-34-12-17

Просмотров: 69


ISSN 2078-5631 (Print)